Roth Capital analyst Kyle Bauser raised the firm’s price target on Sanuwave Health (SNWV) to $54 from $49 and keeps a Buy rating on the shares. The company reported Q2 results that were in line with the company’s preliminary sales announcement, the analyst tells investors in a research note. With the commercial team built out, the updated manufacturing process for its applicator on track for completion in 4Q25, and favorable adoption/awareness of UltraMIST within the provider community, Roth expects strong sales growth and earnings leverage to continue, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNWV: